Amylyx Pharmaceuticals, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Amylyx Pharmaceuticals, Inc. (AMLX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $14.03 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $13.99, a 287.53% increase year-over-year.
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $3.61, a 78.46% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $16.76, a 48.65% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $32.64, a 66.96% increase year-over-year.
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $4.15, a 51.41% decline from fiscal 2024.
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $8.54, a 71.10% decline from fiscal 2023.
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $29.55, a 45.64% increase from fiscal 2022.
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $20.29.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.03 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $13.99 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $4.15 10-K · filed 2026-03-03 | |||
| 2025-09-30 | $3.95 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $3.73 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $3.61 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | $8.54 10-K · filed 2025-03-04 | |||
| 2024-09-30 | $8.56 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $8.56 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | $16.76 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $29.55 10-K · filed 2024-02-22 | |||
| 2023-09-30 | $31.36 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $31.96 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | $32.64 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | $20.29 10-K · filed 2023-03-13 | |||
| 2022-09-30 | $19.22 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | $19.07 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | $19.55 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |